false 0001835579 0001835579 2024-07-08 2024-07-08

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): July 8, 2024

 

 

IKENA ONCOLOGY, INC.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40287   81-1697316

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

Ikena Oncology, Inc.
645 Summer Street, Suite 101
Boston, Massachusetts 02210
(Address of principal executive offices, including zip code)

(857) 273-8343

(Registrant’s telephone number, including area code)

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trade

Symbol(s)

  

Name of each exchange

on which registered

Common Stock, $0.001 par value per share   IKNA   The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On July 8, 2024, the Board of Directors (the “Board”) of Ikena Oncology, Inc. (the “Company”) appointed Jotin Marango, M.D., Ph.D. to serve as the Company’s Chief Operating Officer, effective as of July 15, 2024 (the “Effective Date”), in addition to his role as the Company’s Chief Financial Officer and Head of Corporate Development.

Dr. Marango has served as the Company’s Chief Financial Officer and Head of Corporate Development since April 2022. Prior to joining the Company, he served as Senior Vice President, Chief Business Officer at Aptose Biosciences Inc. (Nasdaq: APTO) from June 2019 to April 2022 and also as its Chief Financial Officer from May 2021 to April 2022. Before that, from September 2017 to April 2019, Dr. Marango worked as an Equity Research Analyst at Roth Capital Partners covering small and mid-cap biotechnology companies focused on hematology, oncology and rare diseases. Dr. Marango also served as Chief Operating Officer at the Samuel Waxman Cancer Research Foundation from 2012 to 2015, where he oversaw venture philanthropy initiatives in therapeutic development. Through his education and career, Dr. Marango has solidified a passion for working in oncology and facilitating growth for businesses looking to make a difference in cancer research. Dr. Marango holds a B.A. in Chemistry with Honors from Harvard University and earned his M.D. and Ph.D. from the Mount Sinai School of Medicine of New York University.

In connection with Dr. Marango’s promotion to Chief Operating Officer, his salary was increased to $470,000 per year, effective as of the Effective Date. Dr. Marango was also granted an option to purchase 400,000 shares of the Company’s common stock, which shall vest upon the Company’s consummation of a strategic transaction as determined by the Board, subject to Dr. Marango’s continuous service relationship with the Company.

There are no arrangements or understandings between Dr. Marango and any other persons pursuant to which Dr. Marango was promoted to Chief Operating Officer. There are no family relationships between Dr. Marango and any director, executive officer or any other person nominated or chosen by the Company to become a director or executive officer. There are no related person transactions (within the meaning of Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission) between Dr. Marango and the Company.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  Ikena Oncology, Inc.
Date: July 12, 2024   By:  

/s/ Mark Manfredi

    Mark Manfredi, Ph.D.
    President and Chief Executive Officer
v3.24.2
Document and Entity Information
Jul. 08, 2024
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001835579
Document Type 8-K
Document Period End Date Jul. 08, 2024
Entity Registrant Name IKENA ONCOLOGY, INC.
Entity Incorporation State Country Code DE
Entity File Number 001-40287
Entity Tax Identification Number 81-1697316
Entity Address, Address Line One Ikena Oncology, Inc.
Entity Address, Address Line Two 645 Summer Street
Entity Address, Address Line Three Suite 101
Entity Address, City or Town Boston
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02210
City Area Code (857)
Local Phone Number 273-8343
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, $0.001 par value per share
Trading Symbol IKNA
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
Ikena Oncology (NASDAQ:IKNA)
Historical Stock Chart
From Aug 2024 to Sep 2024 Click Here for more Ikena Oncology Charts.
Ikena Oncology (NASDAQ:IKNA)
Historical Stock Chart
From Sep 2023 to Sep 2024 Click Here for more Ikena Oncology Charts.